Search Resources (English): Health Canada

Results 1 - 10 of 20

Results

Public opinion survey on key issues pertaining to post-market surveillance of marketed health products in Canada: final report  
http://www.hc-sc.gc.ca/dhp-mps/pubs/medeff/_res-rec/2004-decima_2003_final_rep-rapp/index-eng.php

Presents the results of a survey where Canadians were asked to give their views and opinions on the effectiveness of Health Canada's methods to communicate health product safety information.

 (See Details)
Published: 2003
Canada's adverse drug reaction database

Provides a searchable database that holds information from all adverse drug reaction (ADR) reports currently held in Health Canada's CADRIS (Canadian Adverse Drug Reaction Information System) database, which monitors adverse drug reactions in drugs approved for the Canadian market.

Published: 1965-2004
Transparency and the drug approval process at Health Canada: policy brief  
http://www.whp-apsf.ca/en/documents/trans_policy.html

Argues that the lack of transparency in the drug approval process can lead to inappropriate, unnecessary and sometimes dangerous drug use, and it impedes the development of knowledge and appropriate decision-making.

 (See Details)
Published: 2006
Health Canada's women's health strategy  
http://www.hc-sc.gc.ca/english/women/womenstrat.htm
Sets out Health Canada's Women's Health Strategy and the rational for it. Reviews some of the ways in which the health system has failed to respond adequately to women's health needs and concerns. (See Details)
Published: 1999
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000
Same tune, different lyrics: the Vioxx story  
http://www.cwhn.ca/node/39500
Illustrates the flaws in the Canadian drug approval and drug regulatory processes, using the current Vioxx scandal as example. (See Details)
Published: 2005
Women and adverse drug reactions: reporting in the Canadian context  
http://www.whp-apsf.ca/pdf/fullerReport.pdf
Provides an overview of how Canada's program for reporting Adverse Drug Reactions (ADRs) supports-or doesn't support-an effective women's health strategy related to prescription drug use. (See Details)
Published: 2002, 2003
Transparency and the drug approval process at Health Canada  
http://www.whp-apsf.ca/en/documents/transparency.html
Argues that the federal government is protecting drug companies instead of the public by keeping information about the drug approval process secret. Examines the impact of this on women's health. (See Details)
Published: 2005
Applying gender-based analysis at Health Canada. Introductory course: participant's manual.
Explains what gender-based analysis (GBA) is and why it is used in Health Canada analyses. Provides introductory materials with theoretical frameworks and illustrative case examples and topics for discussion.